Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Business Wire
Primary endpoint met at the interim analysis in MagnetisMM-5 trial demonstrating a statistically significant and clinically meaningful improvement in progression-free survivalSafety was consistent with the known ELREXFIO profile, with no new safety signals identifiedTrial remains ongoing to assess overall survival, a key secondary endpointInterim efficacy results further strengthen confidence in development strategy for ELREXFIO as monotherapy and in combination, across multiple lines of therapy NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment. The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS), as assessed by blinded independent central review (BICR
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer protects $6.4bn heart disease blockbuster from generics, for now [Yahoo! Finance]Yahoo! Finance
- Cryptococcosis Drugs Market Outlook 2026-2036 [Yahoo! Finance]Yahoo! Finance
- Global Pharmaceutical Market Poised to Surpass USD 3.2 Trillion by 2035 – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Pfizer (PFE) had its "neutral" rating reaffirmed by Citigroup Inc..MarketBeat
- 2 High-Yielding Dividend Stocks to Buy for Passive Income in April [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 4/27/26 - Form 4
- 4/27/26 - Form 4
- 4/27/26 - Form 4
- PFE's page on the SEC website